Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Zenz

Showing results (91-100 of 183) with videos related to

Pageof 19
Sort By:
Blood Advances|August 16, 2022
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progressionPau Abrisqueta, Daniel Medina, Guillermo Villacampa, et al.
British Journal of Haematology|August 16, 2005
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II studyMark Ringhoffer, Norbert Blumstein, Bernd Neumaier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantationThorsten Zenz, Richard F Schlenk, Gerhard Glatting, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Nature Communications|June 11, 2021
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemiaVeronika Ecker, Martina Stumpf, Lisa Brandmeier, et al.
Haematologica|January 13, 2018
Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogoninClaudia Dürr, Bola S Hanna, Angela Schulz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood|January 9, 2017
HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signalingRoland Walter, Kuan-Ting Pan, Carmen Doebele, et al.
Haematologica|September 9, 2010
Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysisRené Scholtysik, Markus Kreuz, Wolfram Klapper, et al.
Blood|May 28, 2020
Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell featuresDamien Roos-Weil, Brian Giacopelli, Marine Armand, et al.
Pageof 19

Showing results (91-100 of 183) with videos related to

Sort By:
Pageof 19
Blood Advances|August 16, 2022
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progressionPau Abrisqueta, Daniel Medina, Guillermo Villacampa, et al.
British Journal of Haematology|August 16, 2005
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II studyMark Ringhoffer, Norbert Blumstein, Bernd Neumaier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantationThorsten Zenz, Richard F Schlenk, Gerhard Glatting, et al.
Blood|February 26, 2025
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trialAdalgisa Condoluci, Ilaria Romano, Daniel Dietrich, et al.
Nature Communications|June 11, 2021
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemiaVeronika Ecker, Martina Stumpf, Lisa Brandmeier, et al.
Haematologica|January 13, 2018
Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogoninClaudia Dürr, Bola S Hanna, Angela Schulz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood|January 9, 2017
HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signalingRoland Walter, Kuan-Ting Pan, Carmen Doebele, et al.
Haematologica|September 9, 2010
Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysisRené Scholtysik, Markus Kreuz, Wolfram Klapper, et al.
Blood|May 28, 2020
Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell featuresDamien Roos-Weil, Brian Giacopelli, Marine Armand, et al.
Pageof 19